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ATN-224Myeloid leukemia cellsmaintain a high intracellular ROS level and use redox signals for survival. Themetabolism
of ROS also affects cell fate, including cell death and differentiation. Superoxide dismutases (SODs) are major an-
tioxidant enzymes that have high levels of expression inmyeloid leukemia cells. However, the role of SODs in the
regulation ofmyeloid leukemia cells' biological function is still unclear. To investigate the function of SODs inmy-
eloid leukemia cell death and differentiation, we used myeloid leukemia cell lines K562, MEG-01, TF-1, and HEL
cells for this study. We found that PMA-induced megakaryocytic differentiation in myeloid leukemia cells is ac-
companied by cell death and SOD1 down-regulation, while SOD2 expression is not affected. The role of SOD1 is
veriﬁed when ATN-224, a SOD1 speciﬁc inhibitor, inhibits cell proliferation and promotes cell death in myeloid
leukemia cells without PMA treatment. Moreover, inhibition or silencing of SODs further increases cell death
and decreases polyploidization induced by PMA while they were partially reversed by SOD1 overexpression.
Thus, SOD1 expression is required for myeloid leukemia cell fate determination. In addition, the knockdown of
PKD2 reduces cell death and promotes polyploidization induced by PMA. PMA/PKD2-mediated necrosis via
PARP cleavage involves both SOD1-dependent and -independent pathways. Finally, ATN-224 enhanced the inhi-
bition of cell proliferation by Ara-C. Taken together, the results demonstrate that SOD1 regulates cell death and
differentiation in myeloid leukemia cells. ATN-224 may be beneﬁcial for myeloid leukemia therapy.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Reactive oxygen species (ROS) play many vital roles in myeloid leu-
kemia [1]. This is especially true for chronic myeloid leukemia (CML)
cells, over 95% of which express and use BCR-ABL fusion protein to
maintain a higher-than-normal level of ROS for survival [2]. These
BCR-ABL expressing cells have constitutive active PI3K/AKT pathway
under redox regulation that serves as a survival signal for these cells
[3]. For this reason, they may be more susceptible to further ROS in-
creases. Consequently, antioxidant enzyme levels are also high in
these cells to maintain the delicate ROS balance needed for survival
[1]. It has been demonstrated that the increased ROS level caused by
the down-regulation of SOD1 leads to cell death in murine thymic lym-
phoma WEHI7.2 cells [4]. As a matter of fact, unbalanced increases in
ROS may also lead to both differentiation and death [5,6]. With thesuperoxide dismutase; PMA,
2; CML, chronic myeloid leuke-
y, College ofMedicine, National
).exception of the upstream survival signals, acute myeloid leukemia
(AML) cells behave similarly in many aspects to that of CML cells. AML
patients with Fms-like tyrosine kinase 3 -internal tandem duplications
(FLT3-ITD) mutation constitute about 30% of AML cases and these pa-
tients suffer from poor prognosis [7]. FLT3 increase ROS production via
the activation of p22phox that maintains a higher ROS level in AML
cells [8] and it is essential to their survival. Moreover, inhibition of
PDK1/AKT and FLT3 signaling induces AML cell death [9]. Furthermore,
ROS level increase has been associated in the differentiation of AML cells
[10]. Because both the induction of cell death and differentiation are
valuable strategies for leukemia treatment, understanding the regula-
tion of ROS levels in myeloid leukemia cells is vital to our comprehen-
sion of myeloid leukemia cell biology.
ROS levels can bemaintained via a balance between their biosynthe-
sis and degradation. Inmyeloid leukemia cells, at least two pathways for
the increase in ROS biosynthesis have been identiﬁed. First, BCR-ABL in-
creases ROS levels by using NADPH oxidase 4 (Nox4) to inhibit phos-
phatase 1a (PP1a), a serine threonine phosphatase, and subsequently
activates a survival signal via the PI3K/AKT pathway [3]. Moreover,
phorbol-12-myristate-13-acetate (PMA) activates p22phox, a subunit of
NADPH oxidase, in the same system to increase ROS production,
which results in megakaryocyte-like differentiation [5]. Second, PMA
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plex IV activity during differentiation [11]. Furthermore, ROS increases
may cause mitochondrial damage, leading to cell death [12]. Although
ROS catabolism is well-studied, its regulation of cell differentiation
and cell death is not.
Superoxide dismutases (SODs) are amajor antioxidant enzyme fam-
ily that transforms two superoxide radicals into hydrogen peroxide and
oxygen. There are three SOD isoforms within the family. SOD1 is
expressed in the intermembrane space of mitochondria, the nucleus,
and the cytosol. SOD2 is located in the mitochondrial matrix, while
SOD3 is secreted into the extracellular space [13]. Recently, several re-
ports have suggested that SOD1 may also have signal transduction
functions. In breast cancer, SOD2 down-regulation induces SOD1-
compensated up-regulation for the removal of excess ROS, activating
ERα-dependent unfolded protein response (UPR) in the mitochondria,
and promotes ERα transcriptional activity in the nucleus [14,15]. Al-
though the function of SOD1 in the regulation of myeloid leukemia
cell death and differentiation has not been reported, the results of stud-
ies on other cell types may support this notion. It was reported that in
human primary megakaryocyte (MK), the mRNA expression level of
SOD1 in CD41+ cells is higher than that in CD41− cells [16]. Moreover,
the down-regulation of SOD1mRNA induced by PMA during cell differ-
entiation has been reported in acute leukemia cell lines, such as U937,
HL60, and HEL cells [17,18]. Furthermore, in murine thymic lymphoma,
the inhibition of SOD1 leads to cell death via the nitric oxide-
peroxynitrite-dependent pathway [4]. From these observations, we
may suggest that SODs level indeed plays a role in the control of cell
death and differentiation via the regulation of ROS levels inmyeloid leu-
kemia cells. Understanding how SODs expression affects cell fate inmy-
eloid leukemia cells may shed light on the mechanism involved in their
survival and its relationship to ROS regulation.
The PMA treatment of myeloid leukemia cells is useful for the study
of how ROS balance affects their survival, differentiation, and death.
Both TPO and PMA promote MK-like differentiation in myeloid leuke-
mia cell lines, such as K562, HEL and TF-1 cells, via an increase in ROS
formation [5], which results in polyploidization and megakaryocytic
surface marker (CD41 and CD61) expression [19]. It has long been
established that protein kinase C (PKC) isoforms are involved in mega-
karyocytic leukemia cell differentiation when induced either by
thrombopoietin (TPO) or phorbol 12-myristate 13-acetate (PMA). Sev-
eral PKC isoforms have been reported to be involved in MK differentia-
tion in leukemia cells. PKCβII has been implicated in megakaryocytic
proliferation in K562 cells [20]. PKCε activation may also be involved
in increases in CD41 expression [21,22]. The down-regulation of PKCε
is related to PMA-induced cell death in K562 and TF-1 cells [6].
The role of PKC isoforms in PMA-inducedmegakaryocytic differenti-
ation has been intensive studied [6,20–23]. However, none of the stud-
ied PKC isoforms can account for all of the PMA actions, it is likely that
other PMA-activated proteins are also involved. PKD is a novel subfam-
ily of PKC. It consists of threemembers, PKD/PKD1, PKD2, and PKD3 [24,
25]. Notably, SOD2 gene expression was increased under oxidative
stress in HeLa cells via PKD1 [26]. PKD2 is also involved in platelet gen-
eration [27]. Because PKD2 is the major isoform expressed in leukemia
cell lines [28], the question of whether PKD2 regulates myeloid leuke-
mia cell differentiation andwhether PKD2mediates the PMA regulation
of ROS requires further study.
In the present study, we studied the role of SOD1 and PKD2 in mye-
loid leukemia cell death and differentiation.We used the PMA treatment
of myeloid leukemia cell lines K562, TF-1, HEL, and MEG-01 for our
study. Our results demonstrated that selective SOD1 inhibitor ATN-224
inhibited cell proliferation and promoted cell death inmyeloid leukemia
cell lines. Moreover, SOD1was involved in PMA-dependentmyeloid leu-
kemia cell death and polyploidization Furthermore, SOD1 expression is
down-regulated by PKD2 activation, which also modulates ROS produc-
tion duringmyeloid leukemia cell death andpolyploidization induced by
PMA. Taken together, PMA-induced myeloid leukemia cell death andpolyploidization is mediated by PKD2/SOD1 signaling. Targeting SOD1
is important to myeloid leukemia therapy.
2. Materials and methods
2.1. Cell culture
The human erythroleukemia cell lines K562, TF-1, HEL and MEG-01
were purchased from Bioresource Collection and Research Center
(Taiwan). The cells were maintained in a humidiﬁed 5% CO2, 37 °C
incubator in RPMI medium (Gibco, Carlsbad, CA, USA) supplemented
with 10% fetal bovine serum (FBS) (Gibco), 100 Units/ml penicillin, 100
Units/ml streptomycin, 2 mM L-glutamine, and 1 mM sodium pyruvate
(Caisson, Logan, Utah, USA). For TF-1 cells, 2 ng/ml GM-CSF (MDBio,
Taiwan) was added. For stable cell line selection, 2 μg/ml puromycin
(MDBio) was added. The human embryonic kidney cell line HEK293
was maintained in Dulbecco's modiﬁed Eagle's medium (Hyclone,
Logan, Utah, USA) supplemented with 10% FBS. For experiments, cells
(1.5 × 105 cells per ml) were treated with 25 nM PMA (5 nM for TF-1)
to induce megakaryocytic (MK) differentiation.
2.2. Reagents
Annexin V-FITC was purchased from BD Biosciences (San Jose, CA,
USA). Propidium iodide (PI) and dihydroethidium (DHE)were obtained
from Invitrogen (Carlsbad, CA, USA). Z-VAD-FMK, N-acetyl-L-cysteine
(NAC), cycloheximide, MG132, polybrene, actinomycin D, and nitroblue
tetrazolium chloride (NBT) were obtained from Sigma-Aldrich (St.
Louis, MO, USA). ATN-224 was a gift from Professor Ching-Yuh Chen
(Department of Applied Chemistry, National Chiayi University, Taiwan
(R.O.C.)). Phorbol 12-myristate 13-acetate (PMA), Ara-C, GF109203X,
Gö6976, and CID755673 were acquired from Tocris Bioscience (Bristol,
UK). Dimethyl sulfoxide (DMSO) and riboﬂavin were acquired from
Merck (Whitehouse Station, NJ). The DMSO in the media was less
than 0.1% at the ﬁnal concentration in order to prevent any effect on ac-
tivity. All inhibitors were added 30 min before PMA administration at
the indicated concentrations.
2.3. Antibodies
PKD1/2 and glycophorin A (GPA) antibodies were purchased from
Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). PKD2 antibodies
were purchased from Novus. Antibodies against AKT, pAKT (Ser473),
pERK1/2 (Thr202/Tyr204), pPKD (Ser916), pPKD (Ser744/748), caspase-
3, and caspase-9 were obtained from Cell Signaling Technology (Boston,
MA, USA). Antibodies against pPKD2 (Ser876) and SOD2 were acquired
from Epitomics (Burlingame, CA, USA). Nitrotyrosine was obtained
from Bioss (Massachusetts, USA). Anti-CD41-FITC antibodies were pur-
chased from eBioscience. Anti-CD61-PE antibody was acquired from
BD. Antibodies against SOD1, GAPDH, and a-tubulin were purchased
from GeneTex (California, USA). Anti-PARP-1 antibody was purchased
from BD. Goat anti-rabbit IgG HRP and goat anti-mouse IgG HRP were
obtained from Jackson ImmunoResearch (Suffolk, UK).
2.4. Small hairpin (sh) RNA lentivirus production
shRNA cloneswere acquired from theNational RNAi Core Facility (In-
stitute of Molecular Biology/Genomic Research Center, Academia Sinica,
Taiwan). Lentiviruseswere obtained from theRNAi Core Research Center
of Clinical Medicine, National Cheng Kung University Hospital. The lenti-
viruses were prepared in accordance with standard protocols. Brieﬂy,
4 × 106 293 T cells were co-transfected with 5 μg pCMVΔR8.91, 0.5 μg
pMD.G, and 5 μg pLKO.1 shRNA using Lipofectamine 2000 (Invitrogen)
for 6 h. After 24 h, the supernatants containing viral particles were har-
vested and ﬁltered through 0.45 μm ﬁlters. The cells were infected with
lentivirus in the presence of polybrene (8 μg/ml) and treated with
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shRNA target sequenceswere as follows: scramble shRNA, 5′-AGTTCAGT
TACGATATCATGT-3′; SOD1 shRNA, 221566- 5′-CCGATGTGTCTATTGAAG
ATT-3′; SOD2 shRNA, 320739- 5′-GCACGCTTACTACCTTCAGTA-3′;
PRKD2 shRNA, 1949- 5′-CGTGGCAGTTAAGGTCATTGA-3′, 1950- 5′-
CACGACCAACAGATACTATAA-3′, and 342320- 5′-GTTGGGTGGTTCATTA
CAGCA-3′.
2.5. Trypan blue exclusion assay
K562, TF-1, HEL, and MEG-01 (1.5 × 105 cells/ml) were harvest-
ed and re-suspended with equal volumes of trypan blue. The cells
were counted in a hemocytometer chamber. The percentage of
cells, excluding the dye, was calculated and expressed as percent
viability.
2.6. Flow cytometric analysis
Superoxide production was detected by DHE [29]. The cells were
pre-incubated with DHE at a ﬁnal concentration of 1 μM in phosphate-
buffered saline (PBS) for 15 min at RT and analyzed by FASCalibur
ﬂow cytometer (BD).
Cell death was determined via propidium iodide (PI) (or
FarRed) and Annexin V. The cells were resuspended with Annexin
V/PI for 10–15 min at 4 °C and analyzed via FASCan ﬂow cytometer
(BD).
Cell differentiation was detected via increases in polyploidization
and glycophorin A (GPA), CD41, and CD61 expression levels. In the
polyploidization experiments, cells were ﬁxed with 70% EtOH over-
night, re-suspended in PBS, and stained with PI solution (0.02 mg/ml
PI, 0.1% triton, and 0.2 mg/ml RNase A) for 30 min at RT and analyzed
by FASCan ﬂow cytometer (BD). CD41 and CD61 expression levels
were measured by incubating the cells with anti-CD41-FITC and anti-
CD61-PE antibodies, respectively, for 30 min, and the cells were then
re-suspended in PBS. GPA expression levels were measured by ﬁxing,
permeabilizing, and incubating the cells with anti-GPA antibody for
60 min, and the cells were then re-incubated with Alexa Fluor 488
goat anti-rabbit (Molecular Probes) antibody for 30 min. Finally, the la-
beled cells were analyzed by Accuri C6 ﬂow cytometer (Becton Dickin-
son, San Jose, CA, USA). The data were analyzed with FlowJo software
(Ashland, OR, USA).
For intracellular staining, the cells were harvested and ﬁxed with 4%
formaldehyde for 20 min. Washed the ﬁxed cells and permeabilized by
adding 0.1% triton for 10 min. The cells were stained with antibody
overnight and re-incubated with Alexa Fluor 488 goat anti-rabbit for
30 min. Cells were then analyzed within 12 h by FASCalibur ﬂow
cytometer (BD).
2.7. Cell lysis and Western blotting
A total of 1.5 × 105 cells/ml were lysed in cell extraction buffer
(10 mM Tris.HCl pH 7.4, 100 mM NaCl, 1 mM EDTA, 0.1% SDS, 10%
glycerol, and 1% Triton X-100) with protease inhibitor cocktail
(Sigma-Aldrich) and phosphatase inhibitors (1 mM PMSF, 20 mM
Na3VO4, and 2 mM Na3P2O7). Lysates were centrifuged at 14,500
r.p.m. The supernatants were then collected, normalized by Lowry
method, diluted to 1:3 with 4× SDS-PAGE loading buffer (250 mM
Tris–HCl pH 6.8, 8% SDS, 0.004% bromophenol blue, and 40% glycer-
ol), and boiled for 10 min. Thirty mg of lysates per well were loaded
and electrophoresed on SDS-PAGE gels and transferred to
polyvinylidene ﬂuoride (PVDF) membranes (Pall Corporation, Port
Washington, NY, USA), and Western blot reactions were detected
using Western Lightning Plus-ECL (PerkinElmer, Santa Clara, Cali-
fornia, USA). Membranes were probed with the antibodies and
ﬁlm exposure measurement. Western blot analysis intensity was
measured by Image J (Java-based image processing program, NIH).2.8. In gel SOD1 activity assay
SOD1 activity analysis was performed as previously described
[30]. Brieﬂy, the samples were re-suspended using cell extraction
buffer without SDS. The resultant cell extracts were electrophoresed
directly, without boiling, on a 12% native polyacrylamide gel. After
electrophoresis, the gel was stained with gel staining solutions
(0.05 M potassium phosphate buffer, pH 7.8, 1 mM EDTA, 0.25 mM
nitroblue tetrazolium chloride (NBT), and 0.5 mM riboﬂavin) for
30 min at room temperature in the dark. After incubation, the gel
was exposed to light until transparent bands were observed, the
sites of superoxide scavenging.
2.9. Statistical analysis
The data were expressed asmeans± S.D. (standard deviation) from
at least three experiments. A statistical analysis was performed using
Student's t-test. Statistically signiﬁcant difference was expressed as
*p b 0.05 or **p b 0.01. Excel or Sigma plot software was used.
3. Results
3.1. ATN-224 inhibits myeloid leukemia cell proliferation and promotes cell
death
CML needs to express an increased SOD1 level to counterbalance in-
creased intracellular ROS production [31]. On the other hand, SOD1 level
is elevated in acute myelomonocytic leukemia patient sample [32]. Al-
though whether SOD1 activity plays an important role in AML biology
is still unreported, the role of SOD1 in AML cells may be very similar to
that of CML cells. Therefore, SOD1may be an important target inmyeloid
leukemia therapy. ATN-224 is a selective SOD1 inhibitor that has thera-
peutic potential in the treatment of many types of solid tumors [14,33].
It has been reported that the inhibition of SOD1 induces cell death in
B-cell acute lymphoblastic leukemia (B-ALL) cell lines [12]. However,
whether the inhibition of SOD1 is equally effective in myeloid leukemia
has not been reported. Therefore, we studied whether ATN-224 reduces
myeloid leukemia cell proliferation and induces death. The effect of ATN-
224 on cell proliferation was studied using trypan blue exclusion assay.
As shown in Fig. 1a, ATN-224 dose- and time- dependently inhibited
the proliferation of myeloid leukemia cells, K562, TF-1, HEL, and MEG-
01. Moreover, ATN-224 also dose-dependently induced K562 and TF-1
cell death, as indicated by Annexin V/PI staining (Fig. 1c and d). These
data showed that ATN-224 indeed inhibits myeloid leukemia prolifera-
tion and promotes cell death in these cells.
AKT and ERK1/2 are survival signal in myeloid leukemia cells which
are the downstream of BCR-ABL in CML cells [3,34] while AML cells
also use other signaling pathways to activate these survival signals [9].
As reported in literature, pAKT (Ser473) and pERK1/2 (Thr202/Tyr204)
phosphorylation denote their activation [35,36]. We studied the phos-
phorylation of AKT and ERK1/2 to analyze whether ATN-224 affects
these survival signals. As shown in Supplemental Fig. S1, the phosphor-
ylation of AKT and ERK1/2 were dose-dependently reduced after ATN-
224 treatment in K562, TF-1, and HEL cells.
Peroxynitrite (ONOO−) is produced by the reaction of superoxide
and nitric oxide (NO). SOD1 inhibition results in superoxide accumula-
tion and subsequently increases intracellular peroxynitrite level.
Peroxynitrite may cause cell death by inducing DNA damage and
nitrosylating tyrosine residue in many proteins [4]. Thus, nitrotyrosine
is a speciﬁc biomarker of peroxynitrite formation [37]. We studied
whether ATN-224 increased intracellular superoxide formation. As
shown in Supplemental Fig. S2, the expression level of nitrotyrosine
was increased after ATN-224 treatment in K562 and TF-1 cells by 2.6
and 2.8 fold, respectively. These results showed that ATN-224 may in-
duce death in myeloid leukemia cells via the increase of peroxynitrite
level.
Fig. 1.ATN-224 dose-dependently inhibited cell proliferation and promoted cell death inmyeloid leukemia cells. (a) K562, TF-1, HEL, andMEG-01 cells were treatedwith 0.1, 1, and 10 μM
of ATN-224 for 48 and 96 h. The cell numberwas counted via trypan blue exclusion assay. (b) After 25 nMPMA treatment for 48 h, the cellswere lysed and immunoblottedwith SOD1 and
SOD2. GAPDH was used as an internal control. (c–d) In the presence or absence of ATN-224 pretreatment for 30 min, the cells were harvested and stained with Annexin V/PI after PMA
treatment for 48 h. The relative percentage of Annexin V-positive cells was normalized against control cells. (e–f) In the presence or absence of ATN-224 pretreatment for 30min, the cells
were harvested and ﬁxed after PMA treatment for 96 h. DNA content was measured via PI staining assay. The relative percentage of high-ploidy number (≥8 N) cells was normalized
against control cells. Similar results were obtained fromat least three independent experiments. Values of *p b 0.05 and **p b 0.01were indicated for the various treatments in comparison
to the non-treated culture. Values of #p b 0.05 and ##p b 0.01 were indicated for the various treatments in comparison to the PMA-only culture.
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hanced cell death by PMA
PMA activates p22phox-dependent NADPH oxidase to increase ROS
production and promote myeloid leukemia cell differentiation [5].
Moreover, PMA also induces myeloid leukemia cell death [6]. However,
the role of SOD1 in PMA-induced myeloid leukemia cell death and dif-
ferentiation is still unclear. Therefore, we studied the effect of PMA on
SOD1 expression levels via immunoblotting assay. The results were
shown in Fig. 1b, PMA down-regulated the protein level of SOD1 but
not that of SOD2 in K562 and TF-1 cells. Next, to study the role of
SOD1 in PMA-induced myeloid leukemia cell death and differentiation,
we used ATN-224 to further inhibit the residual SOD1 after PMA admin-
istration. We observed that the further inhibition of SOD1 by ATN-224
dose-dependently increased the percentage of Annexin V-positive
cells from 27.02% to 43% and from 21.72% to 45.51% in PMA-treated
K562 and TF-1 cells, respectively (Fig. 1c and d).
Moreover, ATN-224 reduced the percentage of polyploidy cells
(≥8 N) from 13.2% to 5.36% and from 12.4% to 2.98% in K562 and TF-1
cells, respectively (Fig. 1e and f). Thus, the further inhibition of SOD1
by ATN-224 promoted PMA-induced cell death and reduced differenti-
ation in myeloid leukemia cells.
In order to directly verify the role of SODs, we employed lentiviral
shRNA technology for the study. SOD1 and SOD2 were successfully
knocked down by their respective shRNAs in K562 and TF-1 cells
(Fig. 2a). We measured the intracellular ROS by DHE staining. The
data were normalized against cells infected with scrambled shRNA
after PMA treatment. As shown in Fig. 2b, SOD1 knockdownof increased
intracellular ROS content by 60.9% and by 52.5% in K562 and TF-1 cells,
respectively. The knockdown of SOD2 also had similar effects. More-
over, knockdown of SOD1 increased the relative percentage of Annexin
V-positive cells by 26.6% and by31.8% in K562 andTF-1 cells, respective-
ly. Knockdown of SOD2 increased that by 9.7% and by 20.0% in K562 and
TF-1 cells, respectively (Fig. 2c). Furthermore, knockdown of SOD1 re-
duced the relative percentage of ploidy cells by 32.0% (Fig. 2d) in
K562 cells. The above data showed that the knockdown of SOD1Fig. 2. SOD1was involved in PMA-induced cell death. (a) K562 and TF-1 cells were infectedwith
terials andMethods.”Knockdown efﬁciencywas determined by immunoblottingwith SOD1 and
treatment for 48 h, the SOD1 and SOD2 knockdown cells were stainedwith DHE or Annexin V/P
ﬂuorescence intensity (MFI) and AnnexinV-positive cellswere normalized against control cells.
cells were analyzed via ﬂow cytometry. The relative percentage of ploidy (≥8 N) cells was norampliﬁed the effects of PMA-induced SOD1 down-regulation, including
polyploidization inhibition and death promotion. Moreover, the knock-
down of SOD2 has the same effect on PMA-induced cell death and
polyploidization, while its expression is not regulated by PMA.3.3. Overexpression of SOD1 enhanced polyploidization and reduced cell
death by PMA
To support the notion that SOD1 is involved in PMA-induced mye-
loid leukemia cell death and polyploidization, we used lentiviral vector
to increase SOD1 expression in K562 cells (Fig. 3a). First, we used DHE
staining to examinewhether SOD1 overexpression reduced ROS forma-
tion by PMA. The results showed that SOD1 overexpression signiﬁcantly
reduced PMA-induced ROS formation (Fig. 3b).
It was reported that N-acetyl-L-cysteine (NAC) reduced ROS to non-
toxic products [38]. In order to study the role of ROS in PMA-induced
cell death and differentiation, we used the ROS scavenger NAC for the
study. Fig. 3d showed that NAC dose-dependently reduced the relative
percentage of Annexin V-positive cells from 94.7% to 57.5%. Next,
we studied the effect of SOD1 overexpression on PMA induced cell
death. After PMA treatment for 48 h, cells were stained with Annexin
V and PI for ﬂow cytometry analysis. SOD1 expression reduced Annexin
V-positive cells from 29.29% to 23.02% (Fig. 3c). The relative percentage
of Annexin V-positive cells was normalized against control cells and
showed that SOD1 overexpression reduced Annexin V-positive cells
by 21.4%.We alsomeasured the level of nitrotyrosine byﬂow cytometry
in SOD1 overexpression cells. We observed that compared with vector
only cells, the nitrotyrosine level was decreased by 23.5% in SOD1 over-
expressing cells (Fig. 3e). These data showed that superoxide are at least
partially involved in PMA-induced cell death in K562 cells.
We further examined the effect of SOD1 expression on differentia-
tion markers, polyploidization and CD61 expression (Fig. 3f and g).
SOD1 overexpression increased PMA-induced polyploidization by
59.8%. However, the selectiveMK surfacemarker CD61was only slightly
increased by 12.9% as compared with control cells (vector only). Thelentiviruses encoding for different shRNAs targeting SOD1 and SOD2, as described in “Ma-
SOD2 antibody. Vector encoding scrambled shRNAwas used as a control. (b–c) After PMA
I. The cells were immediately analyzed by ﬂow cytometry. The relative percentage ofmean
(d) After PMA treatment for 96 h, the selected stable clones of SOD1 and SOD2 knockdown
malized against control cells.
Fig. 3. SOD1was involved in PMA-induced differentiation. (a) K562 cells were infected with lentiviruses encoding for the full-length cDNA of SOD1. The expression efﬁciency was deter-
mined via immunoblotting with SOD1 antibody. An empty vector was used as a control. (b–c) After PMA treatment for 48 h, the selected stable clones of SOD1-overexpression cells were
harvested and stained with DHE and Annexin V/PI. The relative percentage of mean ﬂuorescence intensity (MFI) and Annexin V-positive cells was normalized against the control cells.
(d) In the presence or absence of 0.1, 1, and 5 mMNAC pretreatment for 30 min, cells were harvested and stained with Annexin V after PMA treatment for 48 h. The relative percentage
of Annexin V-positive cells was normalized against control cells. (e) After PMA treatment for 48 h, the cells were harvested, ﬁxed, permeabilized, and stained with anti-nitrotyrosine an-
tibody. The cells were analyzed by ﬂow cytometry. The relative percentage of△MFI (MFI of nitrotyrosine minus MFI of anti-FITC only) was normalized against control cells. (f–g) After
PMA treatment for 96 h, the selected stable clones of SOD1-overexpressing cells were stainedwith PI solution and CD61-RPE antibody and analyzed via ﬂow cytometry. The relative per-
centage of ploidy (≥8 N) cells and CD61 expression level was normalized against control cells. Similar results were obtained from at least three independent experiments. Values of
*p b 0.05 and **p b 0.01 were indicated for the various treatments in comparison with the PMA-only culture.
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death and polyploidization by PMA.3.4. PMA regulated SOD1 via translational and post-translational control
In order to investigate themechanism of PMA-induced SOD1 down-
regulation, we used transcriptional, translational, and protein degrada-
tion inhibitors for the study. Transcriptional inhibitor actinomycin D
(ActD) with a concentration up to 100 ng/ml did not reverse SOD1
down-regulation by PMA (Fig. 4a), suggesting that SOD1 down-
regulation was not under transcriptional control. Moreover, pretreat-
ment with either protein synthesis inhibitor cyclohexiamide (CHX)
(Fig. 4b) or proteasome inhibitor MG132 (Fig. 4c) dose-dependently re-
stored SOD1protein levelswhichwas down-regulated by PMA. Because
SOD1 down-regulation will lead to the accumulation of superoxide, we
detected ROS production when K562 cells were treated with these in-
hibitors by using DHE staining. As shown in Fig. 4d, CHX dose-
dependently inhibited ROS production induced by PMA, while MG132
did not (Fig. 4e). Since MG132 itself increases ROS level in K562 cells
[39], we were unable to observe ROS level reduction after MG132 treat-
ment. It is possible that PMA regulates SOD1via post-translationalmod-
iﬁcation that promotes SOD1 degradation. These results indicated that
PMA attenuated SOD1 expression via translation and post-translation
control.3.5. PMA down-regulated SOD1 through PKD2 activation
PMA is a potent PKC activator. Next, we identiﬁed the PKC isoforms
involved in PMA-induced ROS formation by using a classical PKC iso-
form inhibitor, Gö6976 and a general PKC inhibitor, GF109203x. This ap-
proach is commonly used to delineate which PKC families is involved in
a biological process [40]. Gö6976 reversed 4.2% of PMA-induced super-
oxide formation at 5 nM and reduced 55.9% of that at 50 nM, while
GF109203x failed to do so (Supplemental Fig. S3). Although Gö6976 in-
hibits classical PKC isoforms below 10 nM (IC50), it also inhibit PKD iso-
forms at 20 nM (IC50) [24]. Therefore, PKD isoformsmay be involved in
PMA-induced superoxide formation and PKC isoforms may not be
involved.
PKD isoforms have been reported to be involved in ROS regulation
[26]. To conﬁrm the notion that PKD mediates PMA actions in our sys-
tem, we ﬁrst studied whether PKD isoforms were activated by PMA
and which PKD isoform(s) is/are involved. Mihailovic et al. has shown
that myeloid leukemia cells express mainly PKD2 [28]. We used com-
mercially available antibodies to analyze the expression of PKD1 and
PKD2 by using 293 T cells as a positive control [28]. We found that
K562 cells expressed only PKD2, whereas TF-1 cells expressed both
PKD1 and PKD2 (Fig. 5a).
Next, we investigated whether PKD2 is activated by PMA by using
phosphorylation antibodies. PKD2 was phosphorylated at various
sites, as observed in myeloid leukemia cell lines after PMA treatment.
Fig. 4. SOD1 is down-regulated by PMA via translational and post-translational control. In the presence or absence of different concentration of Actinomycin D (Act D), cycloheximide
(CHX), and MG132, K562 cells were harvested after PMA addition for 48 h. (a–c) The cell lysates were immunoblotted with SOD1 and SOD2. GAPDH was used as an internal control.
(d–e) The cells were harvested, stained with DHE, and analyzed via ﬂow cytometry. The relative percentage of mean ﬂuorescence intensity (MFI) was normalized against control cells.
Similar results were obtained from at least three independent experiments. Values of *p b 0.05 and **p b 0.01 were indicated for the various treatments in comparison with the PMA-
only culture.
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cates its active state [41]) increased rapidly within 1 min and was
sustained for 48 h. (2) After 30 min, a mobility shift was observed
using a PKD2-Ser876 (hyper-phosphorylation state [41]) phosphor-
ylation antibody. (3) At auto-phosphorylation site [25], Ser916 ex-
hibited a similar phosphorylation pattern as observed in Ser876.
(4) Phosphorylation at Ser744/748 (a unique phosphorylated site
catalyzed by PKC [42]) had a shorter period of phosphorylation
than that of Ser876. Similar results were observed in PMA-treated
TF-1 cells (Fig. 5b, below). Ser876 phosphorylation indicated that
PKD2 is activated by PMA. Moreover, PKD2 appears to be phosphor-
ylated by multiple kinases and/or at multiple sites, as shown by its
hyper-phosphorylated state after 30 min.
PKD2 has been reported to be involved in BON endocrine cell pro-
liferation/invasion and platelet generation (dense granule secretion)
[27,43]. To determine whether PKD2mediates the PMA regulation of
SOD1 expression levels, we used selective PKD inhibitor CID755673
for the study [44]. K562 and TF-1 cells were treated with PMA with
or without CID755673 treatment for 48 h. The immunoblotting
data showed that CID755673 dose-dependently restored SOD1 ex-
pression in both K562 and TF-1 cells from 0.1 μM to 5 μM (Fig. 5c)
against PMA down-regulation. The results show that the inhibition
of PKD rescued SOD1 expression level after being down-regulated
by PMA.
To further conﬁrm whether PKD2 mediates the down-regulation of
SOD1 expression by PMA, we employed lentiviral shRNA technology.
PKD2 was successfully knocked down by shRNA in both K562 and TF-1
cells (Fig. 5d). After PMA treatment for 24 and 48 h, respectively, we ob-
served that the knockdown of PKD2 reversed both the PMA-induced
down-regulation of SOD1 protein level and activity in K562 cells
(Fig. 5e). Thus, the data conﬁrmed that PKD2 mediated PMA down-
regulation of the SOD1 level.3.6. Down-regulation of PKD2 enhanced polyploidization by PMA
Because PKD2 knockdown reversed SOD1 down-regulation by PMA,
we investigatedwhether PKD2mediates PMA-induced polyploidization
via PKD2 inhibition. In PMA-treated K562 cells, 12.3% of the cells pos-
sessed a high ploidy number ≥8 N.With CID755673 treatment, the pop-
ulationwith high ploidy number (≥8N) increased to 20.1% (Fig. 6a). The
relative percentage of high-ploidy-number (≥8 N) cells was normalized
against control cells. Both K562 and TF-1 cells with high ploidy numbers
(≥8 N) dose-dependently increased from 106.5% to 159.8% and from
97.5% to 145.3%, respectively, after CID755673 treatment from 0.1 μM
to 5 μM (Fig. 6a, right and 6e). Thus, PKD is involved in suppressed
polyploidization in PMA-treated myeloid leukemia cells.
K562 cells are susceptible to chemically induced differentiation.
PMA-induced K562 cells differentiated into megakaryocyte-like cells,
while chemicals such as butyric acid induced K562 cells to differentiate
into erythroid-like cells [45]. We studied the effect of PKD inhibition on
the expressions of PMA-induced MK surface markers CD41 and CD61,
and an erythrocyte surface marker, glycophorin A (GPA), was used as
a control. We observed that CID755673 had no effect on CD41 or
CD61 expression (Fig. 6b), while the basal level of GPA was decreased
in cells treatedwith CID755673 only (Fig. 6b, bottom). These results im-
plied that basal PKD activity might be required for basal level GPA ex-
pression in untreated K562 cells, while it does not mediate PMA-
induced MK surface markers expression.
To further conﬁrm whether PKD2 was involved in increased
polyploidization induced by PMA in myeloid leukemia cell lines, we
studied the effect of PKD2 knockdown on the percentage of cells with
high ploidy numbers (≥8 N) after PMA treatment. As shown in Fig. 6c,
in the two PKD2 knockdown of K562 cells, the percentage of cells
with high ploidy numbers (≥8 N)was increased by 51.8% and 56.8%, re-
spectively, when compared to cells infectedwith scrambled shRNAafter
Fig. 5. PMA activated PKD2 and resulted in SOD1 down-regulation. (a) An immunoblot analysis showed that K562 and TF-1 cells expressed PKD isoforms. 293 T cells served as a control.
(b) K562 and TF-1 cellswere lysed after 25nMPMA treatment for the indicated time and immunoblottedwith the following antibodies: pPKD Ser744/748, pPKD Ser876, pPKD Ser916, and
PKD2. Alpha-tubulin was used as an internal control. (c) In the presence or absence of 0.1, 1, and 5 μM of CID755673 (CID), the cell lysates were immunoblotted with SOD1 and SOD2
antibodies. GAPDH was used as an internal control. (d) The cells were infected with lentiviruses encoding for various shRNAs targeting PKD2. Knockdown efﬁciency was determined
by immunoblottingwith PKD2 antibody. Vector-encoding scrambled shRNAwasusedas a control. (e) The selected stable clones of PKD2-knockdown cellswereharvested after PMA treat-
ment for 24 and 48 h and immunoblotted with SOD1 and SOD2 antibodies, respectively. The relative percentage of SOD1 expression levels was normalized against GAPDH. SOD1 activity
was detected by in gel assay (described as “materials and methods”). Similar results were obtained from at least three independent experiments. Values of *p b 0.05 and **p b 0.01 were
indicated for the various treatments in comparison with the PMA-only culture.
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On the other hand, PKD2 knockdown has no effect on PMA-induced
CD41 and CD61 expression (Fig. 6d). Nonetheless, the expression of
GPA, an erythrocyte surface marker, was also signiﬁcantly reduced in
PKD2 knockdown cells without PMA treatment (Fig. 6d, bottom), as ob-
served in PKD inhibition. Apparently, PKD2 activity suppressed
polyploidization in PMA-treated myeloid leukemia cells. Although it
has no effect on PMA-induced CD41 and CD61 expression, it regulatesGPA expression in untreated K562 cells. PKD2 is activated by PMA,
while PKD2 activation partially attenuated the full-potential
polyploidization induced by PMA.
3.7. Down-regulation of PKD2 reversed cell death by PMA
Because PMA-induced PKD2 activation partially suppressed the
polyploidization induced by PMA, we investigated the effect of PKD2
Fig. 6. The inhibition or knockdown of PKD2 promoted PMA-induced polyploidization. (a, e) In the presence or absence of 0.1, 1, and 5 μM of CID755673 (CID), the cells were harvested,
stainedwith PI solution, and analyzed via ﬂow cytometry after PMA treatment for 96 h. The relative percentage of ploidy (≥8 N) cells was normalized against control cells. (b–d) The cells
were harvested after PMA treatment for 96h and staindwith CD41, CD61, andGPA antibodies, respectively. The relative percentages ofMFIwere normalized against control cells (GPAwas
normalizedwith PMA-treated cells). (c, f) The selected stable clones of PKD2-knockdown cells were harvested after PMA treatment for 96 h, stainedwith PI solution, and analyzed by ﬂow
cytometry. The relative percentage of ploidy (≥8 N) cells was normalized against control cells. Similar results were obtained from at least three independent experiments. Values of
*p b 0.05 and **p b 0.01 were indicated for the various treatments in comparison with the PMA-only culture.
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the role of PKD in PMA-induced cell death by using Annexin V/PI stain-
ing. PKD inhibition by CID755673 showed dose- and time-dependent
reductions of PMA-induced K562 cell death (Fig. 7a and b). Similar re-
sultswere observed in TF-1 cells (Fig. 7b, right). These results suggested
that PKD mediates K562 and TF-1 cell death induced by PMA.
Because PKD inhibitor CID755673 reduced cell death induced by
PMA, we used PKD2 lentiviral shRNA to further conﬁrm this notion.
We examined whether PKD2 knockdown reduced PMA-induced ROS
formation by using DHE staining. The results showed that PKD2 knock-
down signiﬁcantly reduced ROS formation by PMA in K562 and TF-1
cells (Fig. 7c). Next, PKD2 knockdown cells were analyzed via Annexin
V/PI staining assay after PMA treatment for 48 h. The dot plot data
were showed in Fig. 7e. After PMA treatment, the two PKD2 knockdown
cells reduced the percentage of Annexin V-positive cells from 38.74% to
17.08% and 19.28%, respectively. Normalized data were showed below.
These data were normalized against cells infected with scrambled
shRNA after PMA treatment. The two of PKD2 knockdown in K562
cells diminished the percentage of Annexin V-positive cells by 42.1%
and 39.2%, respectively. The knockdown of PKD2 in TF-1 cells alsoshowed similar results. The percentage of Annexin V-positive cells
was decreased by 37.1% and 21.2%, respectively (Fig. 7f) (shPKD2-
342320has similar effect in K562 cells).We alsomeasured nitrotyrosine
level in PKD2knockdown cells. Comparedwith control cells (Scramble),
nitrotyrosine level was decreased by 55.9% and 57.6% respectively in
two PKD2 knockdown cells after PMA treatment (Fig. 7d). The results
conﬁrmed that PKD2 positively regulates PMA-induced myeloid leuke-
mia cell death.3.8. PMA cleaves PARP into active forms via PKD2/SOD1
To examine the mechanism of PMA-induced cell death in myeloid
leukemia cell lines, we studied the possible involvement of caspase 3,
8, and 9 [46]. As shown in Fig. 8a, caspase 3 and 8 were not activated
after PMA administration in K562 cells. Notably, the cleaved forms
(35 kDa and 37 kDa) of caspase 9 were observed after 48 h and were
dose-dependently attenuated by PKD inhibitor CID755673. However,
pan caspase inhibitor Z-VAD-FMK did not reverse the ROS formation in-
duced by PMA (Fig. 8b). Because caspase 9 may be related to MK
Fig. 7. The inhibition and knockdown of PKD2 reduced cell death by PMA. (a) In the presence or absence of 5 μMCID755673 (CID), the cells were harvested, stainedwith Annexin V and PI
solution, and analyzed via ﬂow cytometry after PMA treatment. The percentage of Annexin V-positive cells at indicated time points was represented as a bar chart. (b) In the presence or
absence of 0.1, 1, and 5 μM of CID755673, the cells were stained with Annexin V/PI and analyzed after PMA treatment for 48 h. The relative percentage of Annexin V-positive cells was
normalized against control cells. (c) The PKD2 knockdown cellswereharvested, stainedwithDHE, and analyzed viaﬂowcytometry. The relative percentage ofmeanﬂuorescence intensity
(MFI)was normalized against control cells. (d) After PMA treatment for 48 h, the cellswere harvested,ﬁxed, permeabilized, stainedwith anti-nitrotyrosine antibody, and analyzed by ﬂow
cytometry. The relative percentage of△MFI (MFI of nitrotyrosineminusMFI of anti-FITC only)wasnormalized against control cells. (e) The selected stable clones of PKD2 knockdown cells
were harvested and stainedwith AnnexinV/PI after PMA treatment for 48 h. The relative percentage of AnnexinV-positive cellswas normalized against cells infected by scrambled shRNA.
Similar results were obtained from at least three independent experiments. Values of *p b 0.05 and **p b 0.01were indicated for the various treatments in comparison with the PMA-only
culture.
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mia cell death induced by PMA [47].
There have been reports suggesting that PMA activates PARP in both
thymocytes [48] and human leukemia HL-60 cells [49]. We studied
whether PARP activation was involved in PKD2-mediated PMA-
induced cell death in K562 cells. As shown in Fig. 8c, we observed that
PARP was cleaved into at least three fragments, including both 55 and
44 kDa fragments, after PMA treatment for 48 h. As reported by Gobeil,
S. et al., these unique cleavage products of PARP are consideredmarkers
of necrosis [50]. The knockdown of PKD2 signiﬁcantly reduced PMA-
induced PARP cleavage. The data suggested that PARP cleavage could
be regulated by PKD2 in K562 cells. Therefore, PKD2 is involved in
PMA-induced necrosis in K562 cells. Next, we used ROS scavenger
NAC to study whether PARP activity was regulated by ROS. The data
showed that NAC reduced PARP cleavage in K562 cells (Fig. 8d). We
also use SOD1 knockdown cells to conﬁrm the result. As shown inFig. 8e, PMA-induced cleavage of PARP was enhanced in SOD1 knock-
down cells. These indicated that PARP signaling is involved in the
PKD2/SOD1-mediated K562 cell death induced by PMA.
3.9. ATN-224 enhances Ara-C-induced inhibition effect on myeloid
leukemia proliferation
In order to study whether ATN-224 enhances the therapeutic effect
of free-radical generating chemotherapeutic agents, we used cytarabine
(cytosine arabinoside or Ara-C) for the study. Ara-C is clinically used for
the treatment of myeloid leukemia [51]. To investigate that whether
Ara-C increases intracellular ROS level inmyeloid leukemia cells, we ob-
served that Ara-C dose increased intracellular ROS in K562, TF-1, MEG-
01, and HEL cells by using DHE staining assay (Fig. 9a). Next, we studied
whether ATN-224 enhanced the inhibition of cell proliferation by Ara-C.
Co-treatment with Ara-C and ATN-224 at different dosage also
Fig. 8. PMA/PKD2/SOD1-mediated cell deathwas related to PARP activation and ROS production. (a) In the presence or absence of 0.5, 1, and 5 μMCID755673 (CID), the cell lysates were
immunoblottedwith antibodies against caspase 3, 8, and 9. GAPDHwas used as an internal control. (b) In thepresence or absence of 0.1, 1, and 10 μMZ-VAD-FMK, the cellswere harvested
and stained with DHE and FarRed dye, respectively. The relative percentage of DHE/FarRed double-stained cells was normalized against control cells. (c, e) The cells were harvested after
PMA treatment for 24 and 48 h. The cell lysates were immunoblotted with PARP antibody. GAPDHwas used as an internal control. (d) In the presence or absence of 5 mMNAC, the cells
were harvested and immunoblotted with PARP antibody after PMA treatment for 24 and 48 h. GAPDH was used as an internal control.
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blue exclusion assay (Fig. 9b). These data indicated that ATN-224
enhances Ara-C-induced inhibition effect on myeloid leukemia
proliferation.
4. Discussion
The intracellular ROS level in myeloid leukemia cells is vital to
the regulation of cell fate, including cell death and differentiation.Fig. 9. ATN-224 enhanced the inhibition of proliferation by Ara-C inmyeloid leukemia cells. (a)
DHE, and analyzed via ﬂow cytometry. The relative percentage of mean ﬂuorescence intensity (
treatedwith indicated concentration of ATN-224 and Ara-C for 72 h. The cell number was coun
experiments. Values of *p b 0.05 and **p b 0.01were indicated for the various treatments in com
the various treatments in comparison with the ATN-224-only culture.Although antioxidant molecules, such as SODs, play a major role in the
modulation of ROS levels, their role in the regulation of myeloid leuke-
mia cell death and differentiation is still largely unknown. In this study,
we studied the role of SODs in the regulation of cell death and differen-
tiation. Myeloid cell lines K562, TF-1, HEL, and MEG-01, which were
treated with PMA, were used as a study model. We discovered
that the inhibition of SOD1 reduces cell survival via inhibition of
phosphorylation of AKT and ERK1/2 and promotes cell death through
increasing peroxynitrite formation. Moreover, the inhibition orIn the presence or absence of 10 and 100 nMAra-C, the cells were harvested, stained with
MFI) was normalized against control cells. (b) K562, TF-1, HEL, andMEG-01 cells were co-
ted via trypan blue exclusion assay. Results were obtained from at least three independent
parisonwith the Ara-C-only culture. Values of #p b 0.05 and##p b 0.01were indicated for
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polyploidization induced by PMA. SOD1 can be regulated by PKD2,
a PKC isoform, probably via translational and post-translational
control. PKD2/SOD1 induced cell death through PARP cleavage and
peroxynitrite formation, which is induced by PMA. Finally, we also
found that ATN-224 enhances the inhibition of proliferation by Ara-C.
These ﬁndings help us to understand the physiological functions of
SOD1 in myeloid leukemia cell death and differentiation regulation
and may also indicate a role for ATN-224 in myeloid leukemia
treatment.
ROS play an important role in myeloid leukemia cells cell prolifera-
tion, death, and differentiation. ROS level can be regulated via a subtle
balance between biosynthesis and degradation. In myeloid leukemia
cells, ROS formation can be increased by NADPH oxidase 4 (NOX4) acti-
vation, which in turn activates the pro-proliferative molecule Fyn and
encourages the survival of myeloid leukemia cells [1]. ROS may also be
further increased via the activation of NADPH oxidase subunit p22phox,
which promotes megakaryocytic differentiation in myeloid leukemia
cell lines such as K562 and HEL [5]. Apparently, any further increase in
ROS that overwhelms the antioxidant system may result in cell death
[52].
Myeloid cells TF-1, K562, and HEL differentiate into MK under PMA
treatment that requires ROS increase [5]. Therefore, ROS balance regula-
tionmay be the common factor that determines their fate. Although the
role of ROS in AML cells are not studied as extensively as that of CML
cells, recent studies suggested that ROS regulation is also vital to AML bi-
ology [a recent review can be found in [53]]. Our study suggests that
ROS increase induced by SODs inhibition or knockdown inhibits prolif-
eration signals such as AKT or ERK1/2 in both CML and AML cells.We ob-
served that ATN-224 dose-dependently inhibits cell proliferation in TF-
1, HEL, K562, and MEG-01 cells (Fig. 1a). The anti-proliferation effect of
ATN-224 is likely due to its ability to inhibit both ATK and ERK1/2 activa-
tion (Supplemental Fig. S1).Moreover, both SOD1 inhibition and knock-
down enhance cell death (Fig. 1c and d).
MG132 also affects NFκB that may have an effect on ROS generation.
Since MG132 itself increases ROS level in K562 cells [39], we were un-
able to observe ROS level reduction afterMG132 treatment.Wehave in-
creased the concentration of MG132 without success while cell death
increased. Using another 26S proteasome inihibitor bortezomib, while
more selective, it caused serious cell death using the suggested concen-
trations (data not shown). Similar observation were made by other re-
searchers on K562 cells [39,54]. From the results shown in Fig. 3d and
e, it is possible that PMA regulates SOD1 via translation of an unknown
protein mediator or through post-translational modiﬁcation that pro-
motes SOD1 degradation. However, it is not yet conclusive.
SODs aremajor ROS degradation enzymes that transform superoxide
into hydrogen peroxide. SOD1mRNA down-regulated by PMA has been
showed in acute leukemia cell lines (U937, HL60, and HEL) [17,18]. In
our study, the expression level of SOD1 was down-regulated in myeloid
lukemia cell lines (K562 and TF-1) (Fig. 1b) during differentiation. How-
ever, the role of SODs in myeloid leukemia cell differentiation remains
unclear. In our study system, PMA plays a role in both inducing death
and differentiation, while increasing ROS production via p22phox.
Thus, PMA may mimic SOD1 down-regulation when it provides addi-
tional free radical production. We observed that increased SOD1
expression via infection before PMA treatment actually enhances
PMA-induced polyploidization (Fig. 3f). Therefore, the PMA down-
regulation of SOD1 expression actually hampers polyploidization. Previ-
ous studies have shown that exogenous hydrogen peroxide promotes
polyploidization by PMA [16]. Based on our results, reduced SOD1 may
attenuate hydrogen peroxide production, which conﬁrms the vital role
of hydrogen peroxide in MK cell cycle regulation. This may explain
why PMA-induced polyploidization in MK cell lines seldom exceeds
n N 32.
The localization of SOD1 in the nucleus or the mitochondria may be
related to polyploidization. The question of whether SOD1 regulates cellcycle proteins, such as p21, via hydrogen peroxide or is involved in in-
teractions with cyclins through SOD1 nuclear translocation [14,55] re-
quires further study. Recently, Huang R. et al. [11] used cyclosporin A
to stabilize mitochondrial membrane potential and promote PMA-
induced MK surface marker CD41 and CD61 expression. Because SOD1
is also located in the inter membrane space of the mitochondria, we
can expect that SOD1 will degrade the ROS that are produced by respi-
ratory chain complex IV to stabilize the mitochondrial membrane po-
tential and enhance polyploidization.
The physiological functions of SODs in myeloid leukemia cells may
be different from those in breast cancer. In breast cancer, SOD1 up-
regulation compensated for the down-regulation of SOD2 and removed
excess ROS [14,15]. Our data show that the knockdown of either SOD1
or SOD2 increases ROS formation and cell death, and reduces poly-
ploidization induced by PMA (Fig. 2b, c, and d). However, SOD2 is not
regulated by PMA (Fig. 1b). The knockdown of either SOD1 or SOD2
did not enhance the expression of their counterparts (Fig. 2a). More-
over, SOD1 overexpression also did not affect SOD2 expression levels
(Fig. 3a).
Therapies targeting SOD1 have been studied in some hematological
tumors, such as diffuse large B-cell lymphoma and acute T-cell lympho-
blastic leukemia [4,12]. Moreover, the knockdown of SOD1 also en-
hances CD34+ K562 cell sensitivity to imatinib treatment [31]. Here,
we investigated the effect of ATN-224 on myeloid leukemia cells. We
observed that ATN-224 inhibits myeloid leukemia cell proliferation
and induces cell death (Fig. 1a, c, andd).Moreover, knockdownof either
SOD1 or SOD2 promotes cell death and inhibits polyploidization in-
duced by PMA (Fig. 2c and d). We suggest that the inhibition of both
SOD1 and SOD2may act synergistically in myeloid leukemia treatment.
PKD2 is a PKC isoform that is activated by PMA. PMA is a highly
potent PKC activator that activates cPKC, nPKC, and PKD, while it has
no action on aPKC, which has no diacylglycerol (DAG) binding site
[56]. Jacquel et al. observe that PKCα, β, γ, δ, and ε translocate from
the cytosol to the membrane within 15 min after PMA treatment in
K562 cells [23]. Thus, all available PKC and PKD isoformsmay be activat-
ed by PMA simultaneously. In our results, we observed biphasic PKD
phosphorylation after PMA treatment, including an early phase and a
hyper-phosphorylation phase. Our results suggest that during the
early phase of PMA action, PMA simultaneously activates multiple
PKC/PKD isoforms within 30 min. In the hyper-phosphorylation phase,
a mobility shift was observed from 30 min to 48 h after PMA treatment
(Fig. 5b). These activated kinases further interact with their neighboring
proteins. Unlike the activation of a single receptor, which has clear cel-
lular objective, the result of PMA treatment is chaotic. The effect of PMA
treatment is probably the summation of the effects of all activated PKC/
PKD isoforms and their subsequent interactions. Therefore, both differ-
entiation and death signals are observed after the PMA activation of
PKC/PKD isoforms.
We also observed that PKD2 plays an important role in myeloid leu-
kemia cell death and differentiation. The lineage control of erythrocyte–
megakaryocyte is important for myeloid leukemia differentiation. PKCε
has been reported to be involved in regulating megakaryocytic lineage
commitment through functional cooperationwithGATA-1 in the activa-
tion of theCD41promoter [22]. However, PKCε alone cannot account for
other PMAactions inmyeloid leukemia cells. In our study,we found that
PKD2 is involved in PMA-induced MK differentiation, while PKD2 regu-
lates basal erythroid marker GPA expression (Fig. 6b and d). It has been
reported that BCR-ABL phosphorylates PKD2 at Tyr438 [28], while other
reports have suggested that Bcr-Abl inhibitor imatinib promotes GPA
expression in K562 cells [57]. In this study, we observed that PMA in-
duced the phosphorylation of PKD2 at Ser876 (Fig. 5b). The knockdown
of PKD2 decreased the basal level expression of GPA (Fig. 6d). These
data suggested the possibility that BCR-ABL may regulate GPA expres-
sion via PKD2. We also demonstrated a new function of PKD2 in that
it suppressed polyploidization in myeloid leukemia differentiation in-
duced by PMA, while its basal activity maintains GPA expression. To
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control of myeloid leukemia cells.
PKD2 regulates myeloid leukemia cell death via SOD1. Our data
show that endogenous PKD2may promote SOD1 turnover. Interesting-
ly, PKD2 knockdown reversed 50–60% of cell death induced by PMA,
while SOD1 overexpression reversed PMA-induced cell death at a rate
of about 20% (Figs. 3c and 7e). The data suggest that PKD2 increased
myeloid leukemia cell death induced by PMA and that this may also in-
volve a SOD1-independent pathway. Previous studies have shown that
the down-regulation of PKCε relates to PMA-induced K562 and TF-1 cell
death [6]. In our data, PKD2 activation is related to PMA-induced K562
and TF-1 cell death. Thus, PKCε and PKD2 may have opposing actions
in PMA treatment.
Themechanismof PMA-induced cell death inmyeloid leukemia cells
was investigated. In our study, PMA caused necrosis through the activa-
tion of PKD2, which down-regulates SOD1 and cleaves PARP (Figs. 5e
and 8c). Inhibition of SOD1 by ATN-224 increases peroxynitrite levels
in K562 and TF-1 cells (Supplemental Fig. S2) indicating an increase in
superoxide formation leading to cell death. Moreover, SOD1 knock-
down where it increases PMA induced ROS formation (Fig. 2b and
c) while SOD1 overexpression attenuates the increase in ROS and
peroxynitrite formation by PMA (Fig. 3b and e). Furthermore, PKD2
knockdown reduced superoxide and peroxynitrite formation in PMA
pretreated cells (Fig. 7c and d). Therefore, PMA down-regulation SOD1
expression via PKD2 results in increase in ROS and peroxynitrite forma-
tion inmyeloid leukemia cells. Similar results are seen in K562 cells that
are co-treated with hemin and TPA: the degradation of PARP is blocked
by the PKC inhibitor bisindolylmaleimide II [58]. The major 55 and
minor 44 kDa fragments of cleaved PARP are the active fragments
[59]. These fragments amplify PARP activity and result in the depletion
of ATP pools. Prolonged ATP depletion inevitably causes necrotic death
[60]. Themitochondrial inter membrane space is related to ATP synthe-
sis [14]. In our study, we observed that PMA down-regulates SOD1 ex-
pression levels, while PARP was cleaved into three different cleaved
forms (Fig. 8c). Thus, we suggested that SOD1 down-regulation reduces
the superoxide removal rate, which probably disturbs ATP synthesis ef-
ﬁciency in the electron transport chain.
5. Conclusions
ROS generating chemotherapeutic agents enjoyed some success in
myeloid leukemia treatment. In chronic lymphocytic leukemia, the
non-selective SOD inhibitor 2-methoxyestradiol enhances arsenic triox-
ide (a ROS inducer) cytotoxicity [61]. However, inmany situations, they
suffer from high cytotoxicity to normal cells and drug resistancemay be
developed. Understanding the ROS metabolic system in myeloid leuke-
mia cells may help to solve this problem. In this study, we showed that
SOD1 knockdown increase intracellular ROS level that causes cell death
in myeloid leukemia cells (Fig. 2b). Apparently, SOD1 inhibitor may in-
crease the therapeutic effect of ROS generating chemotherapeutic
agents to myeloid leukemia cells. This notion is supported by the fact
that SOD1 inhibitor ATN-224 is usedwith ROS generating drug Ara-C in-
hibits proliferation inmyeloid leukemia cells (Fig. 9a and b). ATN-224 is
undergoing some clinical trials and was reported as “well-tolerated”
[62,63]. Thus ATN-224may be useful as an adjuvant in treatment ofmy-
eloid leukemia.
Conﬂict of interest
The authors have declared that no competing interests exist.
Author contributions
Yu-Lin Chen performed experiments, analyzed data, and wrote the
paper. Wai-Ming Kan designed the study, discussed the results and
edited the paper.Acknowledgments
This research received funding from the Headquarters of University
Advancement at the National Cheng Kung University (Grant number:
D100-35B32), which is sponsored by theMinistry of Education, Taiwan,
ROC.Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2015.07.025.References
[1] P.S. Hole, R.L. Darley, A. Tonks, Do reactive oxygen species play a role inmyeloid leu-
kemias? Blood 117 (2011) 5816–5826.
[2] S.J. Stein, A.S. Baldwin, NF-kappaB suppresses ROS levels in BCR-ABL(+) cells to pre-
vent activation of JNK and cell death, Oncogene 30 (2011) 4557–4566.
[3] R. Naughton, C. Quiney, S.D. Turner, T.G. Cotter, Bcr-Abl-mediated redox regulation
of the PI3K/AKT pathway, Leukemia 23 (2009) 1432–1440.
[4] K. Lee, M.M. Briehl, A.P. Mazar, I. Batinic-Haberle, J.S. Reboucas, B. Glinsmann-
Gibson, L.M. Rimsza, M.E. Tome, The copper chelator ATN-224 induces
peroxynitrite-dependent cell death in hematological malignancies, Free Radic.
Biol. Med. 60 (2013) 157–167.
[5] J.L. Sardina, G. Lopez-Ruano, L.I. Sanchez-Abarca, J.A. Perez-Simon, A. Gaztelumendi,
C. Trigueros, M. Llanillo, J. Sanchez-Yague, A. Hernandez-Hernandez, p22(phox)-
dependent NADPH oxidase activity is required for megakaryocytic differentiation,
Cell Death Differ. 17 (2010) 1842–1854.
[6] M. Vitale, G. Gobbi, P. Mirandola, C. Carubbi, C. Micheloni, C. Malinverno, P. Lunghi,
A. Bonati, Phorbol ester-induced PKC epsilon down-modulation sensitizes AML cells
to TRAIL-induced apoptosis and cell differentiation, Blood 113 (2009) 3080–3087.
[7] D.G. Gilliland, J.D. Grifﬁn, Role of FLT3 in leukemia, Curr. Opin. Hematol. 9 (2002)
274–281.
[8] T. Maraldi, C. Prata, F.V.D. Sega, C. Caliceti, L. Zambonin, D. Fiorentini, G. Hakim,
NAD(P)H oxidase isoform Nox2 plays a prosurvival role in human leukaemia cells,
Free Radic. Res. 43 (2009) 1111–1121.
[9] Z.H. Zeng, I.J. Samudio, W.G. Zhang, Z. Estrov, H. Pelicano, D. Harris, O. Frolova, N.
Hail, W.J. Chen, S.M. Kornblau, P. Huang, Y.L. Lu, G.B. Mills, M. Andreeff, M.
Konopleva, Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3
signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and ap-
optosis in acute myelogenous leukemia, Cancer Res. 66 (2006) 3737–3746.
[10] C. Callens, S. Coulon, J. Naudin, I. Radford-Weiss, N. Boissel, E. Raffoux, P.H.M. Wang,
S. Agarwal, H. Tamouza, E. Paubelle, V. Asnaﬁ, J.A. Ribeil, P. Dessen, D. Canioni, O.
Chandesris, M.T. Rubio, C. Beaumont, M. Benhamou, H. Dombret, E. Macintyre, R.C.
Monteiro, I.C. Moura, O. Hermine, Targeting iron homeostasis induces cellular differ-
entiation and synergizes with differentiating agents in acute myeloid leukemia, J.
Exp. Med. 207 (2010) 731–750.
[11] R. Huang, L. Zhao, H. Chen, R.H. Yin, C.Y. Li, Y.Q. Zhan, J.H. Zhang, C.H. Ge, M. Yu, X.M.
Yang, Megakaryocytic differentiation of K562 cells induced by PMA reduced the ac-
tivity of respiratory chain complex IV, PLoS One 9 (2014) e96246.
[12] K. Lee, M.R. Hart, M.M. Briehl, A.P. Mazar, M.E. Tome, The copper chelator ATN-224
induces caspase-independent cell death in diffuse large B cell lymphoma, Int. J.
Oncol. 45 (2014) 439–447.
[13] L. Miao, D.K. St Clair, Regulation of superoxide dismutase genes: implications in dis-
ease, Free Radic. Biol. Med. 47 (2009) 344–356.
[14] L. Papa, G. Manfredi, D. Germain, SOD1, an unexpected novel target for cancer ther-
apy, Genes Cancer 5 (2014) 15–21.
[15] L. Papa, M. Hahn, E.L. Marsh, B.S. Evans, D. Germain, SOD2 to SOD1 switch in breast
cancer, J. Biol. Chem. 289 (2014) 5412–5416.
[16] Y. Ojima, M.T. Duncan, R.W. Nurhayati, M. Taya,W.M.Miller, Synergistic effect of hy-
drogen peroxide on polyploidization during the megakaryocytic differentiation of
K562 leukemia cells by PMA, Exp. Cell Res. 319 (2013) 2205–2215.
[17] J.H. Auwerx, A. Chait, G. Wolfbauer, S.S. Deeb, Loss of copper-zinc superoxide dis-
mutase gene expression in differentiated cells of myelo-monocytic origin, Blood
74 (1989) 1807–1810.
[18] T. Kamiya, J. Makino, H. Hara, N. Inagaki, T. Adachi, Extracellular-superoxide dismut-
ase expression during monocytic differentiation of U937 cells, J. Cell. Biochem. 112
(2011) 244–255.
[19] H.W. Shen, Y.L. Chen, C.Y. Chern,W.M. Kan, The effect of prostacyclin agonists on the
differentiation of phorbol ester treated human erythroleukemia cells, Prostaglan-
dins Other Lipid Mediat. 83 (2007) 231–236.
[20] N.R. Murray, G.P. Baumgardner, D.J. Burns, A.P. Fields, Protein kinase C isotypes in
human erythroleukemia (K562) cell proliferation and differentiation. Evidence
that beta II protein kinase C is required for proliferation, J. Biol. Chem. 268 (1993)
15847–15853.
[21] A.N. Goldfarb, L.L. Delehanty, D. Wang, F.K. Racke, I.M. Hussaini, Stromal inhibition
of megakaryocytic differentiation correlates with blockade of signaling by protein
kinase C-epsilon and ERK/MAPK, J. Biol. Chem. 276 (2001) 29526–29530.
[22] F.K. Racke, D.Wang, Z. Zaidi, J. Kelley, J. Visvader, J.W. Soh, A.N. Goldfarb, A potential
role for protein kinase C-epsilon in regulating megakaryocytic lineage commitment,
J. Biol. Chem. 276 (2001) 522–528.
2675Y.-L. Chen, W.-M. Kan / Biochimica et Biophysica Acta 1853 (2015) 2662–2675[23] A. Jacquel, M. Herrant, V. Defamie, N. Belhacene, P. Colosetti, S. Marchetti, L. Legros,
M. Deckert, B. Mari, J.P. Cassuto, P. Hofman, P. Auberger, A survey of the signaling
pathways involved in megakaryocytic differentiation of the human K562 leukemia
cell line by molecular and c-DNA array analysis, Oncogene 25 (2006) 781–794.
[24] J. Chen, G. Lu, Q.J. Wang, Protein kinase C-independent effects of protein kinase D3
in glucose transport in L6 myotubes, Mol. Pharmacol. 67 (2005) 152–162.
[25] Y. Fu, C.S. Rubin, Protein kinase D: coupling extracellular stimuli to the regulation of
cell physiology, EMBO Rep. 12 (2011) 785–796.
[26] P. Storz, H. Doppler, A. Toker, Protein kinase D mediates mitochondrion-to-nucleus
signaling and detoxiﬁcation from mitochondrial reactive oxygen species, Mol. Cell.
Biol. 25 (2005) 8520–8530.
[27] O. Konopatskaya, S.A. Matthews, M.T. Harper, K. Gilio, J.M.E.M. Cosemans, C.M.
Williams, M.N. Navarro, D.A. Carter, J.W.M. Heemskerk, M. Leitges, D. Cantrell,
A.W. Poole, Protein kinase C mediates platelet secretion and thrombus formation
through protein kinase D2, Blood 118 (2011) 416–424.
[28] T. Mihailovic, M. Marx, A. Auer, J. Van Lint, M. Schmid, C. Weber, T. Seufferlein, Pro-
tein kinase D2 mediates activation of nuclear factor kappaB by Bcr-Abl in Bcr-
Abl + human myeloid leukemia cells, Cancer Res. 64 (2004) 8939–8944.
[29] H.T. Zhao, S. Kalivendi, H. Zhang, J. Joseph, K. Nithipatikom, J. Vasquez-Vivar, B.
Kalyanaraman, Superoxide reacts with hydroethidine but forms a ﬂuorescent prod-
uct that is distinctly different from ethidium: potential implications in intracellular
ﬂuorescence detection of superoxide, Free Radic. Biol. Med. 34 (2003) 1359–1368.
[30] V.C. Culotta, L.W. Klomp, J. Strain, R.L. Casareno, B. Krems, J.D. Gitlin, The copper
chaperone for superoxide dismutase, J. Biol. Chem. 272 (1997) 23469–23472.
[31] L. Liu, R. Chen, S. Huang, Y. Wu, G. Li, Q. Liu, D. Yin, Y. Liang, Knockdown of SOD1
sensitizes the CD34+ CML cells to imatinib therapy, Med. Oncol. 28 (2011)
835–839.
[32] A. Naz, T.S. Shamsi, A. Sattar, T. Mahboob, Oxidative stress and total antioxidant sta-
tus in acute leukemia at diagnosis and post remission induction phase, Pak. J. Pharm.
Sci. 26 (2013) 1123–1130.
[33] A. Glasauer, L.A. Sena, L.P. Diebold, A.P. Mazar, N.S. Chandel, Targeting SOD1 reduces
experimental non-small-cell lung cancer, J. Clin. Invest. 124 (2014) 117–128.
[34] J.A. McCubrey, L.S. Steelman, W.H. Chappell, S.L. Abrams, E.W. Wong, F. Chang, B.
Lehmann, D.M. Terrian, M. Milella, A. Tafuri, F. Stivala, M. Libra, J. Basecke, C.
Evangelisti, A.M. Martelli, R.A. Franklin, Roles of the Raf/MEK/ERK pathway in cell
growth, malignant transformation and drug resistance, Biochim. Biophys. Acta
1773 (2007) 1263–1284.
[35] D.D. Sarbassov, D.A. Guertin, S.M. Ali, D.M. Sabatini, Phosphorylation and regulation
of Akt/PKB by the rictor-mTOR complex, Science 307 (2005) 1098–1101.
[36] D. Stokoe, S.G.Macdonald, K. Cadwallader, M. Symons, J.F. Hancock, Activation of Raf
as a result of recruitment to the plasma-membrane, Science 264 (1994) 1463–1467.
[37] H. Ferry-Dumazet, M. Mamani-Matsuda, M. Dupouy, F. Belloc, D. Thiolat, G. Marit,
M. Arock, J. Reiffers, M.D. Mossalayi, Nitric oxide induces the apoptosis of human
BCR-ABL-positive myeloid leukemia cells: evidence for the chelation of intracellular
iron, Leukemia 16 (2002) 708–715.
[38] O.I. Aruoma, B. Halliwell, B.M. Hoey, J. Butler, The antioxidant action of N-
acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide,
and hypochlorous acid, Free Radic. Biol. Med. 6 (1989) 593–597.
[39] A. Zanotto, A. Delgado-Canedo, R. Schroder, M. Becker, F. Klamt, J.C.F. Moreira, The
pharmacological NF kappa B inhibitors BAY117082 and MG132 induce cell arrest
and apoptosis in leukemia cells through ROS-mitochondria pathway activation,
Cancer Lett. 288 (2010) 192–203.
[40] V.O. Rybin, A. Sabri, J. Short, J.C. Braz, J.D. Molkentin, S.F. Steinberg, Cross-regulation
of novel protein kinase C (PKC) isoform function in cardiomyocytes. Role of PKC ep-
silon in activation loop phosphorylations and PKC delta in hydrophobic motif phos-
phorylations, J. Biol. Chem. 278 (2003) 14555–14564.
[41] S. Sturany, J. Van Lint, F. Muller, M. Wilda, H. Hameister, M. Hocker, A. Brey, U. Gern,
J. Vandenheede, T. Gress, G. Adler, T. Seufferlein, Molecular cloning and characteriza-
tion of the human protein kinase D2. A novel member of the protein kinase D family
of serine threonine kinases, J. Biol. Chem. 276 (2001) 3310–3318.
[42] R.T. Waldron, O. Rey, T. Iglesias, T. Tugal, D. Cantrell, E. Rozengurt, Activation loop
Ser744 and Ser748 in protein kinase D are transphosphorylated in vivo, J. Biol.
Chem. 276 (2001) 32606–32615.
[43] L.N. Jackson, J. Li, L.A. Chen, C.M. Townsend, B.M. Evers, Overexpression of wild-type
PKD2 leads to increased proliferation and invasion of BON endocrine cells, Biochem.
Biophys. Res. Commun. 348 (2006) 945–949.[44] E.R. Sharlow, K.V. Giridhar, C.R. Lavalle, J. Chen, S. Leimgruber, R. Barrett, K. Bravo-
Altamirano, P. Wipf, J.S. Lazo, Q.J. Wang, Potent and Selective Disruption of Protein
Kinase D Functionality by a Benzoxoloazepinolone, J. Biol. Chem. 283 (2008)
33516–33526.
[45] B. Chenais, I. Molle, C. Trentesaux, P. Jeannesson, Time-course of butyric acid-
induced differentiation in human K562 leukemic cell line: rapid increase in
gamma-globin, porphobilinogen deaminase and NF-E2 mRNA levels, Leukemia 11
(1997) 1575–1579.
[46] J.M. Lai, C.L. Hsieh, Z.F. Chang, Caspase activation during phorbol ester-induced ap-
optosis requires ROCK-dependent myosin-mediated contraction, J. Cell Sci. 116
(2003) 3491–3501.
[47] M.J. White, S.M. Schoenwaelder, E.C. Josefsson, K.E. Jarman, K.J. Henley, C. James,
M.A. Debrincat, S.P. Jackson, D.C. Huang, B.T. Kile, Caspase-9 mediates the apoptotic
death of megakaryocytes and platelets, but is dispensable for their generation and
function, Blood 119 (2012) 4283–4290.
[48] C. Hegedus, P. Lakatos, G. Olah, B.I. Toth, S. Gergely, E. Szabo, T. Biro, C. Szabo, L.
Virag, Protein kinase C protects from DNA damage-induced necrotic cell death by
inhibiting poly(ADP-ribose) polymerase-1, FEBS Lett. 582 (2008) 1672–1678.
[49] M. Bhatia, J.B. Kirkland, K.A. Meckling-Gill, Modulation of poly(ADP-ribose) poly-
merase during neutrophilic and monocytic differentiation of promyelocytic (NB4)
and myelocytic (HL-60) leukaemia cells, Biochem. J. 308 (Pt 1) (1995) 131–137.
[50] S. Gobeil, C.C. Boucher, D. Nadeau, G.G. Poirier, Characterization of the necrotic
cleavage of poly(ADP-ribose) polymerase (PARP-1): implication of lysosomal prote-
ases, Cell Death Differ. 8 (2001) 588–594.
[51] R.R. Ellison, J.F. Holland, M. Weil, C. Jacquillat, M. Boiron, J. Bernard, A. Sawitsky, F.
Rosner, B. Gussoff, R.T. Silver, A. Karanas, J. Cuttner, C.L. Spurr, D.M. Hayes, J. Blom,
L.A. Leone, F. Haurani, R. Kyle, J.L. Hutchison, R.J. Forcier, J.H. Moon, Arabinosyl cyto-
sine: a useful agent in the treatment of acute leukemia in adults, Blood 32 (1968)
507–523.
[52] C.M. Troy, D. Derossi, A. Prochiantz, L.A. Greene, M.L. Shelanski, Downregulation of
Cu/Zn superoxide dismutase leads to cell death via the nitric oxide-peroxynitrite
pathway, J. Neurosci. 16 (1996) 253–261.
[53] F. Zhou, Q. Shen, F.X. Claret, Novel roles of reactive oxygen species in the pathogen-
esis of acute myeloid leukemia, J. Leukoc. Biol. 94 (2013) 423–429.
[54] N. Selvi, B.T. Kaymaz, C. Gunduz, C. Aktan, H.D. Kiper, F. Sahin, M. Comert, A.F. Selvi,
B. Kosova, G. Saydam, Bortezomib induces apoptosis by interacting with JAK/STAT
pathway in K562 leukemic cells, Tumour Biol. 35 (2014) 7861–7870.
[55] Y. Fan, H. Chen, B. Qiao, Z. Liu, L. Luo, Y. Wu, Z. Yin, c-Jun NH2-terminal kinase de-
creases ubiquitination and promotes stabilization of p21(WAF1/CIP1) in K562 cell,
Biochem. Biophys. Res. Commun. 355 (2007) 263–268.
[56] Y. Nishizuka, S. Nakamura, Lipidmediators and protein kinase C for intracellular sig-
nalling, Clin. Exp. Pharmacol. Physiol. Suppl. 22 (1995) S202–S203.
[57] A. Jacquel, P. Colosetti, S. Grosso, N. Belhacene, A. Puissant, S. Marchetti, J.P.
Breittmayer, P. Auberger, Apoptosis and erythroid differentiation triggered by Bcr-
Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit differ-
ent sensitivity to caspase inhibition, Oncogene 26 (2007) 2445–2458.
[58] C.C. Chou, C.Y. Hsu, Involvement of PKC in TPA-potentiated apoptosis induction dur-
ing hemin-mediated erythroid differentiation in K562 cells, N.-S. Arch. Pharmacol.
379 (2009) 1–9.
[59] G.M. Shah, R.G. Shah, G.G. Poirier, Different cleavage pattern for poly(ADP-ribose)
polymerase during necrosis and apoptosis in HL-60 cells, Biochem. Biophys. Res.
Commun. 229 (1996) 838–844.
[60] P. Pacher, C. Szabo, Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway
in human disease, Am. J. Pathol. 173 (2008) 2–13.
[61] J.L. Sardina, G. Lopez-Ruano, B. Sanchez-Sanchez, M. Llanillo, A. Hernandez-
Hernandez, Reactive oxygen species: are they important for haematopoiesis? Crit.
Rev. Oncol. Hematol. 81 (2012) 257–274.
[62] S.A. Lowndes, A. Adams, A. Timms, N. Fisher, J. Smythe, S.M. Watt, S. Joel, F. Donate,
C. Hayward, S. Reich, M. Middleton, A. Mazar, A.L. Harris, Phase I study of copper-
binding agent ATN-224 in patients with advanced solid tumors, Clin. Cancer Res.
14 (2008) 7526–7534.
[63] J. Lin, M. Zahurak, T.M. Beer, C.J. Ryan, G. Wilding, P. Mathew, M. Morris, J.A.
Callahan, G. Gordon, S.D. Reich, M.A. Carducci, E.S. Antonarakis, A non-
comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc super-
oxide dismutase inhibitor, in patients with biochemically recurrent hormone-naive
prostate cancer, Urol. Oncol. 31 (2013) 581–588.
